Surging Geriatric Population Supporting the Wet Age-Related Macular Degeneration Sector Growth
The growing
prevalence of age-related macular degeneration (AMD), lack of specific
treatment availability, and increase in geriatric population are driving the
growth of the wet age-related macular degeneration market.
The market
is projected to generate revenue worth $10.4 billion in 2024, witnessing a CAGR
of 7.1% during the forecast period (2019–2024).
AMD is a disease in which blurred vision or blindness occurs due to
damage to the retina macula. Wet AMD is a type of AMD characterized by the
growth of abnormal blood vessels under the retina and macula.
Based on the
age group, the wet age-related macular degeneration market is categorized into drugs
that are given to people aged 40–59 years, 60–80 years, and above 80 years. Out
of these, in 2018, wet AMD drugs prescribed to people above 80 years of age
contributed nearly 60.0% revenue to the market. Due to growing prevalence of
the disease in the geriatric population, the market is expected to witness
significant progress in the forecast period.
Request
to Get the Sample Pages at:
The risk of
developing AMD is directly proportional to age. With the number of people aged
60 years and above rising, the prevalence of AMD is also increasing. According
to the World Population Prospects data published by the United Nations (UN), in
2017, there were about 962 million people in the age group 60 years or over
across the globe, and the number is predicted to more than double by 2050,
reaching 2.1 billion ultimately. Thus, it can be concluded that the geriatric
population is rising faster than younger age groups.
Japan,
Germany, Italy, and Portugal are among the nations with the largest population
of elderly in the world. As older people are more prone to degenerative
disorders, the increasing geriatric population in these countries is
anticipated to contribute to the rising demand for drugs for wet AMD treatment,
thus driving the wet age-related macular degeneration market during the
forecast period.
Therefore,
the surging geriatric population across the world is pushing the demand for
drugs for treating wet AMD, resulting in the growth of the market.
Comments